ClinicalTrials.gg
Not yet recruitingNCT07556471Updated Apr 29, 2026

Evaluation of the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo

A Phase 2 interventional study of Experimental LW402 Tablet and Placebo in Non-Segmental Vitiligo (NSV), sponsored by Shanghai Longwood Biopharmaceuticals Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Shanghai Longwood Biopharmaceuticals Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to assess the efficacy, safety, and tolerability of LW402 tablets in participants with non-segmental vitiligo.

Drawing on the prior/preclinical data of LW402 tablets, this clinical trial will incorporate three dose groups: 50 mg twice daily (BID), 100 mg BID, and 150 mg BID. The trial will be structured into a screening period (maximum 5 weeks), a treatment period (52 weeks, encompassing a 24-week main trial phase and a 28-week extension phase), and a safety follow-up period (4 weeks). The maximum duration of participation in this study will be 61 weeks.

Following the completion of 24-week data collection for all trial participants, unblinding will be performed in accordance with the pre-specified procedure. Subsequently, based on the unblinded data results, regulatory communication will be conducted with the Center for Drug Evaluation (CDE) regarding the initiation of the Phase III confirmatory clinical trial. Participants who have undergone unblinding will continue to attend scheduled study visits to complete the trial.

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to assess the efficacy, safety, and tolerability of LW402 tablets in participants with non-segmental vitiligo.

Drawing on the prior/preclinical data of LW402 tablets, this clinical trial will incorporate three dose groups: 50 mg twice daily (BID), 100 mg BID, and 150 mg BID. The trial will be structured into a screening period (maximum 5 weeks), a treatment period (52 weeks, encompassing a 24-week main trial phase and a 28-week extension phase), and a safety follow-up period (4 weeks). The maximum duration of participation in this study will be 61 weeks.

Following the completion of 24-week data collection for all trial participants, unblinding will be performed in accordance with the pre-specified procedure. Subsequently, based on the unblinded data results, regulatory communication will be conducted with the Center for Drug Evaluation (CDE) regarding the initiation of the Phase III confirmatory clinical trial. Participants who have undergone unblinding will continue to attend scheduled study visits to complete the trial.

Eligible trial participants will be stratified by disease severity (T-VASI \< 15 vs. ≥ 15) and randomly allocated in a 1:1:1:1 ratio to three active treatment groups (50 mg BID, 100 mg BID, and 150 mg BID) and one placebo group. The planned sample size is 45 participants per group, with a total of 180 participants expected to be enrolled. Following 24 weeks of continuous dosing, participants in the placebo group will be re-randomized in a 1:1:1 ratio to the 50 mg BID, 100 mg BID, and 150 mg BID treatment groups for continued dosing until Week 52.

02

Conditions studied

  • Non-Segmental Vitiligo (NSV)

Browse trials for

Keywords

  • LW402 Tablets,Phase II,Non-segmental Vitiligo
03

In context

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

This study's planned enrollment of 180 is above the median of 36 across 265 interventional studies indexed under Vitiligo.

Browse Vitiligo studies →

Lead sponsor

Shanghai Longwood Biopharmaceuticals Co., Ltd. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 75 years (inclusive), with no restriction on gender;
  • Clinically diagnosed with non-segmental vitiligo at screening;
  • At the screening visit and baseline visit, the Facial Vitiligo Area Scoring Index (F-VASI) is ≥ 0.5 and the Total Vitiligo Area Scoring Index (T-VASI) is ≥ 3;
  • At the screening visit and baseline visit, the disease is in the progressive stage or stable stage;

Exclusion criteria

Exclusion Criteria:

  • Individuals with a known allergy to Janus kinase inhibitors;
  • Segmental vitiligo, mixed vitiligo, or undetermined vitiligo;
  • White hair is present in more than 33% of facial skin lesions due to vitiligo, or in more than 33% of total skin lesions due to vitiligo;
  • Skin lesions due to vitiligo are restricted to hairless areas, or hairless regions account for ≥30% of the lesion sites (e.g., lips, palms, fingers, labia);
  • Individuals with other active hypopigmentary conditions during the screening period (including but not limited to Vogt-Koyanagi-Harada syndrome, hypopigmentation associated with malignant tumors [melanoma and mycosis fungoides], post-inflammatory hypopigmentation, pityriasis alba [a mild manifestation of atopic dermatitis], senile leukoderma [age-related depigmentation], chemical/drug-induced leukoderma, ataxia-telangiectasia, tuberous sclerosis complex, melasma, and congenital hypopigmentary disorders [including piebaldism, Waardenburg syndrome, hypomelanosis of Ito, incontinentia pigmenti, hereditary symmetrical dyschromatosis, xeroderma pigmentosum, and nevus depigmentosus]) are excluded. Note: Coexisting halo nevus (also referred to as Sutton nevus) is permitted;
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    LW402 50mg,PO.BID

    LW402 Tablet,50mg,BID

    Drug: Experimental LW402 Tablet

  • Experimental
    LW402 100mg,PO.BID

    LW402 Tablet,100mg,BID

    Drug: Experimental LW402 Tablet

  • Experimental
    LW402 150mg,PO.BID

    LW402 Tablet,150mg,BID

    Drug: Experimental LW402 Tablet

  • Placebo comparator
    LW402 Placebo

    LW402 Placebo Tablet,BID

    Drug: Placebo

Interventions

  • DrugExperimental LW402 Tablet

    LW402 Tablets

  • DrugPlacebo

    LW402 Placebo Tablets

06

What researchers measure

Primary outcomes

  1. Percentage change in F-VASI at Week 24 relative to baseline

    Evaluation of the efficacy of LW402 tablets in the treatment of non-segmental vitiligo in trial participants at 24 weeks

    Time frame: Baseline to Week 24

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Feb 2028, 20 months later.

Of 44 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's planned 20 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
Apr 29, 2026
StartEst.
May 31, 2026
Primary completionEst.
Feb 1, 2028
CompletionEst.
Dec 31, 2028
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07556471
Lead sponsor
Shanghai Longwood Biopharmaceuticals Co., Ltd.
Collaborators
Clinical Service, China
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
May 31, 2026 (estimated)
Primary completion
Feb 1, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 29, 2026

Study contacts

Barbara Chen
Contact
barbara@lwbiopharma.com
+86-21-63634910
Leihong Xiang, Doctor
principal investigator · Huashan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion